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Abstract
Background: The most prevalent neglected tropical diseases are treated through blanket drug distribution that
is reliant on lay community medicine distributors (CMDs). Yet, treatment rates achieved by CMDs vary widely and it
is not known which CMDs treat the most people.
Methods: In Mayuge District, Uganda, we tracked 6779 individuals (aged 1+ years) in 1238 households across 31
villages. Routine, community-based mass drug administration (MDA) was implemented for schistosomiasis,
lymphatic filariasis, and soil-transmitted helminths. For each CMD, the percentage of eligible individuals treated
(offered and ingested medicines) with at least one drug of praziquantel, albendazole, or ivermectin was examined.
CMD attributes (more than 25) were measured, ranging from altruistic tendencies to socioeconomic characteristics
to MDA-specific variables. The predictors of treatment rates achieved by CMDs were selected with least absolute
shrinkage and selection operators and then analyzed in ordinary least squares regression with standard errors
clustered by village. The influences of participant compliance and the ordering of drugs offered also were
examined for the treatment rates achieved by CMDs.
Results: Overall, only 44.89% (3043/6779) of eligible individuals were treated with at least one drug. Treatment rates
varied amongst CMDs from 0% to 84.25%. Treatment rate increases were associated (p value< 0.05) with CMDs who
displayed altruistic biases towards their friends (13.88%), had friends who helped with MDA (8.43%), were male (11.
96%), worked as fishermen/fishmongers (14.93%), and used protected drinking water sources (13.43%). Only 0.24%
(16/6779) of all eligible individuals were noncompliant by refusing to ingest all offered drugs. Distributing
praziquantel first was strongly, positively correlated (p value < 0.0001) with treatment rates for albendazole and
ivermectin.
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Conclusions: These findings profile CMDs who treat the most people during routine MDA. Criteria currently used
to select CMDs—community-wide meetings, educational attainment, age, years as a CMD, etc.—were
uninformative. Participant noncompliance and the provision of praziquantel before albendazole and ivermectin did
not negatively impact treatment rates achieved by CMDs. Engaging CMD friend groups with MDA, selecting CMDs
who practise good preventative health behaviours, and including CMDs with high-risk occupations for endemic
infections may improve MDA treatment rates. Evidence-based guidelines are needed to improve the monitoring,
selection, and replacement of CMDs during MDA.
Keywords: Mass drug administration, Coverage, Sub-Saharan Africa, Schistosomiasis, Lymphatic filariasis, Soil-
transmitted helminths, Compliance, Praziquantel, Albendazole, Ivermectin,
Background
Neglected tropical diseases (NTDs) comprise a set of 20
distinct ailments, which predominantly affect individuals
living in rural poor areas of low-income countries [1].
The most prevalent NTDs are schistosomiasis, lymph-
atic filariasis, and soil-transmitted helminths (STHs) [2].
These chronic infections afflict an estimated more than
one billion people worldwide and, if left untreated, can
cause debilitating and irreversible morbidity [2, 3]. Schis-
tosomiasis may contribute to portal hypertension and
hepatosplenomegaly for Schistosoma mansoni and S.
japonicum and bladder cancer for Schistosoma haemato-
bium [4]. Lymphatic filariasis may result in severe
hydrocoeles (men) and lymphoedema [5]. Amongst
STHs, hookworm can cause anaemia, diarrhoea, and
protein malnutrition [6].
The most widely implemented treatment strategy for
schistosomiasis, lymphatic filariasis, and STHs relies on
lay healthworkers/volunteers from NTD-endemic com-
munities. Mass drug administration (MDA) is a
diagnosis-free annual/biannual distribution of single-dose,
oral preventive chemotherapies within NTD-endemic
areas [7]. Concerning the quantity of dosage forms do-
nated by pharmaceutical companies and the number of
at-risk people targeted/treated, MDA is the largest infec-
tious disease treatment programme worldwide [3, 8].
However, at least 1/3rd of at-risk individuals requiring
treatment do not receive preventive chemotherapies [3].
The most common MDA implementation uses commu-
nity medicine distributors (CMDs). CMDs are unpaid vol-
unteers apart from reimbursement for the training
received from the local Ministry of Health. Members of
endemic villages nominate individuals to serve as CMDs
who are then responsible for treating all village residents
eligible for MDA.
The provision of treatment using CMDs has been eval-
uated with respect to varying procedures for nominating
CMDs [9, 10], understanding incentives/motivations of
CMDs [10–12], measuring participant drug uptake rates
[13, 14], and more recently examining the influence of
CMD social networks [15–18]. These studies [9–14]
have contributed to the understanding of how to retain
CMDs throughout multiple years of MDA using kinship
structures, the high opportunity costs incurred by CMDs
when distributing medicine instead of working to earn
income, and the challenges of participant willingness to
ingest medicines provided by CMDs. The evaluation of
CMDs thus far also has revealed biases towards socio-
economically marginalized individuals [15, 19] and how
tightly-knit CMD friendships positively affect the reach
and speed of MDA [17]. However, the aforementioned
evaluations focus on cross-sectional or village-level data.
There remains, to our knowledge, no quantitative study
identifying the best-performing CMDs by observable,
e.g. socioeconomic attributes. The main reason for this
knowledge gap is that there is a need to deconstruct
treatment rates by individual CMD. In this study, we
examine treatment rates by CMD and comprehensively
profile all CMDs responsible for treating an estimated
more than 40,000 people for MDA. We address the
following question. Who are the CMDs who treat the
most people?
Methods
Study area and MDA tracking
Routine MDA was tracked from mid-July to mid-August
in 2016 for 31 villages with an estimated 41,582 people
eligible for treatment (Additional file 1: supplementary
methods). The villages were located within 5 km of Lake
Victoria and across six sub-counties (at the time of sur-
vey) within Mayuge District. The same vector control of-
ficers and one district health officer oversaw the study
villages and were responsible for the training and moni-
toring of CMDs. The sub-counties were chosen based
on (1) current eligibility for the routine round of MDA
studied here, (2) ongoing distribution of the same set of
drugs during MDA, (3) ongoing implementation of
community-based MDA, and (4) having had the same
number of previous rounds of MDA [17]. The specific
study villages were chosen due to the endemicity with
intestinal schistosomiasis (S. mansoni) and hookworm;
infection prevalence for individuals aged 5+ years was
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36% and 41%, respectively [20]. Prevalence of lymphatic
filariasis in the study area is less than 5% [21].
In 2003, Uganda was the first country to receive
MDA—both school and community-based—for schisto-
somiasis [22]. Community-based MDA was provided to
treat individuals with praziquantel for schistosomiasis
and with albendazole and ivermectin for lymphatic filar-
iasis. Albendazole was not donated for community-wide
treatment of hookworm; however, individuals in our
study area benefited from ongoing albendazole distribu-
tion for lymphatic filariasis [20]. At the time of this
study, our villages had received at least 10 annual
rounds of community-based MDA for schistosomiasis
and STHs.
Two CMDs per village were tasked with treating all
eligible individuals within their village, i.e. children (in-
cluding both enrolled and non-enrolled schoolchildren)
and adults. During the study period, school-based MDA
had not yet begun (for schistosomiasis and STHs) and
drugs were only available from CMDs. To emphasize,
CMDs were responsible for administering all treatments
for schistosomiasis, STHs, and lymphatic filariasis within
their villages. The eligible treatment groups included
school-aged children and adults with praziquantel for
schistosomiasis; preschool-aged children, school-aged
children, and adults with albendazole for STHs; and
school-aged children and adults with albendazole and
ivermectin for lymphatic filariasis.
The CMDs were trained to move from door-to-door
to administer and observe ingestion of the required
medicines. This procedure is the only nationally ap-
proved method of distribution for community-based
MDA in the study area. Hence, community-based MDA
here differs from community-directed MDA in that the
village members are neither choosing how MDA is im-
plemented, e.g. door-to-door versus central point distri-
bution or a combination thereof, nor deciding the days/
timing when MDA occurs. Community-based and
community-directed MDA are similar with regard to
one key aspect of community-wide MDA—both select
CMDs through community-wide meetings. The CMDs
were instructed by national programmes to administer
praziquantel in week 1 and albendazole with ivermectin
in week 2 of MDA. All CMDs were provided a sufficient
number of all pills/tablets to treat everyone for the
aforementioned infections in their village. To remove
administrative barriers during MDA, vector control offi-
cers were provided with a car to ensure CMDs received
timely training and initiated MDA at the same time [17].
Although the national programme instructs CMDs to
administer treatment within 2 weeks, drugs are not re-
trieved from the villages after 2 weeks and drug delivery
by CMDs predominantly occurs over at least a 1-month
period in the study area [17]. Thus, to enable a
comprehensive tracking of MDA, routine MDA pro-
ceeded undisturbed for 1 month as opposed to 2 weeks.
After the 1-month period, surprise visits from survey
teams were conducted in all villages [17, 19].
Participant sampling
Forty households were systematically randomly sampled
in each village using local registrers where all current
residents were listed by household (Additional file 1:
supplementary methods). As this study was data-driven,
sample size calculations were conducted to achieve
high precision and accuracy. We assumed there were
8000 households across the 31 study villages (final
count was 7452 households) and treatment rates of
50% (conservative at the household level for our study
area [17]). Accordingly, 613 households were needed
to achieve a 99% confidence level with a 5% confi-
dence interval. However, households were grouped by
village, so to allow for a generous design effect, 613
was multiplied by two resulting in 1226 households
required. A common denominator of 40 households
per village was chosen to enable comparisons amongst
CMDs across villages. Ultimately, 6779 individuals (all
members of sampled households aged 1+ years) in
1238 households across 31 villages had complete data
and were examined in this study (Fig. 1). Information
on all CMDs—two per village—also was gathered. This
analysis focused on the 59 CMDs (total possible = 62)
with complete data. Additional details of MDA
tracking and participant sampling are provided in
Additional file 1: supplementary methods.
Variables
Treatment rates for each CMD were calculated as the
percentage of eligible individuals in the village—1+ years
for albendazole and 5+ years for praziquantel/ivermec-
tin—who were treated by the CMD of interest. Treat-
ment comprised the offer of at least one drug of
praziquantel, albendazole, or ivermectin by a CMD and
the recipient’s ingestion of at least one offered drug
(Fig. 1). For each treated individual, household survey
respondents reported the main type of location of where
drugs were received from CMDs. This categorical vari-
able included the participants’ home, local health cen-
tres, primary schools, participants’ friends’ houses,
CMDs’ houses, and the chairman’s (village leader’s)
home. Participant noncompliance was measured for all
drugs; it was defined as the offer of a drug to an eligible
individual who refused to ingest the offered drug. For all
eligible individuals who did not comply with at least one
treatment or were not offered any treatment, the reasons
from the perspective of the participant for noncompli-
ance or no offer were recorded. No limit was placed on
the number of reasons/responses from an individual. An
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eligible individual could have not complied with a treat-
ment and still be classified as treated as long as the indi-
vidual consumed at least one drug. Notably, the World
Health Organization (WHO) treatment targets for the
diseases of interest here are as follows: at least 75%
treatment of at-risk individuals with praziquantel or
albendazole, respectively, for schistosomiasis and STHs;
and at least 65% of eligible individuals with both alben-
dazole and ivermectin for lymphatic filariasis [7]. The
number of CMDs who met these targets was described,
although WHO targets are defined for communities and
nonexistent for individual CMDs.
A
B
Fig. 1 Treatment outcomes. PZQ praziquantel, ALB albendazole, IVM ivermectin. A treated individual was someone eligible for MDA and who
was offered and ingested at least one drug of PZQ, ALB, or IVM from a CMD during 1 month of MDA. A treated household comprised at least
one eligible person in the home who was offered and had ingested at least one drug of PZQ, ALB, or IVM from a CMD during 1 month of MDA.
a Breakdown of treatment outcomes for 31 villages by household and individual. b Scatter plot of treatment outcomes for CMDs. Pearson
r = 0.968, p < 0.0001
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We examined who treated whom as follows. For each
individual offered at least one drug, the name of the
CMD who offered the drug(s), was recorded from the
household survey respondent (Additional file 1: supple-
mentary methods). If both CMDs offered a drug to an
individual, then both CMDs’ names were recorded.
Hence, the percentage of individuals treated by each
CMD cannot necessarily be added together and equated
to the percentage of individuals treated in the village.
CMDs are selected by their fellow community members
and thus are well known throughout their village [17].
No respondents indicated that they did not know the
name of the two CMDs within their village. Similarly, no
respondents reported that they did not know the name
of the CMD(s) who offered drugs to a particular house-
hold member. To minimize any recall bias, respondents
only provided information about those treated within
their household and did not provide information on
which drug each CMD provided to each individual.
Thus, if an individual within a home was offered more
than one drug by more than one CMD, then both CMDs
were recorded as giving all drugs offered.
To assess intrinsic motivations, altruistic tendencies of
CMDs were measured as follows. CMDs were asked to
make a choice amongst three options of pre-divided
sums of money. The choices provided to CMDs are
shown in Tables 1 and 2. Each option had an amount of
money that the CMD would receive and an amount of
money another individual would receive. The highest
payoff was 5500 Ugandan shillings, which was approxi-
mately equal to half of what CMDs would receive for re-
muneration for attending a full day of MDA training or
the value of 1 day of casual labour in the study area [11].
The lowest payoff was 500 Ugandan shillings for the
other individual. The amounts were chosen so that
CMDs would make decisions about amounts that were
not trivial, i.e. too low within the local context, or con-
versely were not too high to avoid decisions that would
result in a major change in living standards of the CMD.
Each option represented a different well-established so-
cial value orientation [23]. This task was repeated six
times with each CMD. The number of altruistic choices
was counted and, as described in van Lange [23], if a
CMD chose an altruistic response at least five times,
then the CMD was classified as altruistic. This game
was conducted twice for each CMD where the identity
of the other/receiving individual was either a complete
stranger or a close friend (Tables 1 and 2). The complete
protocol for the prosocial game and definition of social
value orientations are provided in the Additional file 1:
supplementary methods. Two variables were constructed
from these games: baseline altruism and in-group bias.
Baseline altruism was a binary variable of the CMD’s
altruism classification towards strangers, and in-group
bias was a binary variable equal to one if the CMD was
classified as altruistic towards close friends, but not
towards strangers.
A wide range of CMD attributes was measured. The
status-seeking behaviour of a CMD was measured as a
binary variable equal to one if the CMD purposely
sought at least one of their current close friendships
with a person of formal (high) status [15]. Formal status
was defined as currently holding or having previously
held a position within the local council (village govern-
ment), on the beach management committee, or as a re-
ligious/tribe/clan leader. CMDs were asked who
nominated them to be a CMD, if/how their friends
helped with MDA, and the number of years they had
been active as a CMD. Eleven socioeconomic character-
istics of CMDs also were calculated. To account for the
placement of each CMD in their village social network,
which has been shown to affect village-level treatment
rates [17], the connections between CMDs and only
Table 1 Prosocial games: stranger outside the village who you
will never meet
A B C
You 3500 4200 4000
Stranger 500 2000 3000
You 4000 5000 5300
Stranger 4000 1000 2000
You 5500 5000 5000
Stranger 3000 4500 1000
You 5400 4800 5000
Stranger 3000 1000 5000
You 4800 5400 4800
Stranger 4800 2400 800
You 5000 4500 5200
Stranger 500 4000 2200
Table 2 Prosocial games: one of your close friends
A B C
You 4800 5400 4800
Close friend 4800 2400 800
You 5500 5000 5000
Close friend 3000 4500 1000
You 3500 4200 4000
Close friend 500 2000 3000
You 5000 4500 5200
Close friend 500 4000 2200
You 4000 5000 5300
Close friend 4000 1000 2000
You 5000 4800 5400
Close friend 5000 1000 3000
Chami et al. BMC Medicine           (2019) 17:69 Page 5 of 16
their immediate friends were graphed. CMDs named
up to 10 close friends and these friends were interviewed
to elicit their relations with the CMD and other
CMD-nominated individuals. Six network indicators were
examined to assess the cohesiveness/sparseness of friend-
ship connections. Comprehensive descriptions for all
variables are provided in Additional file 1: supplementary
methods, Table S1, Table S2, and Table S3.
Statistical analysis
Data were analyzed in R v3.2.3, Stata v13.1, and Python
v2.7.11. With a comprehensive set of 25 CMD character-
istics and only 59 CMDs, the final set of variables used
to predict treatment rates were chosen using a
data-driven approach—the least absolute shrinkage and
selection operator (Lasso)—described in [24]. For Lasso,
ordinary least squares regression (OLS) was used with a
variable penalization based on the absolute value of coef-
ficients; variables with non-zero coefficients were kept
and used as predictors of treatment rates achieved by
CMDs [24]. Mixed models allowing for village-level ran-
dom effects were compared to simple OLS models with
a single intercept; there was no support for use of a
mixed model (likelihood ratio test p value > 0.20). Thus,
for the final model, OLS regressions were run with ro-
bust standard errors clustered by village to account for
any village-level variation such as differences in the
number of households per village or the compactness of
the spatial dispersion of homes. To assess internal model
validity, eight-fold cross-validation was run for both the
variable selection and final OLS model.
Results
Treatment variation by CMD
Only 44.89% (3043/6779) of all individuals eligible for at
least one drug were treated within 1 month of MDA
(Obs. 62 CMDs). Only 11.73% (357/3043) of all treated
individuals were offered drugs by both CMDs. In 51.61%
(16/31) of villages, no eligible individuals were treated
by both CMDs (Obs. 62 CMDs). Praziquantel was the
most often administered medicine. Treatment rates for
praziquantel, albendazole, and ivermectin were 40.99%
(2393/5838), 36.29% (2460/6779), and 29.74% (1736/
5838), respectively. The average treatment rate per CMD
was low. Considering the conservative administration of
at least one drug, CMDs treated an average of only
26.08% of eligible individuals (Obs. 59 CMDs, std. dev.
21.79%). These treatment rates varied widely across
CMDs from 0% to 84.25% (Table 3); 10.17% (6/59) of
CMDs did not treat a single person in their village.
CMDs who treated many people did not simply ap-
proach a few large households. The percentage of indi-
viduals treated by CMDs was strongly positively
correlated (Pearson's r = 0.968, p < 0.0001) with the per-
centage of households approached by CMDs (Fig. 1 and
Additional file 1: supplementary methods).
Participant noncompliance
Noncompliance was infrequent and did not contribute
to the low treatment rates achieved by CMDs. Figure 2
presents the breakdown of noncompliance by drug and
reason. Only 0.24% (16/6779) of eligible individuals were
noncompliant by refusing to ingest all offered drugs.
Amongst treated individuals, a further 32 eligible indi-
viduals refused to ingest at least one of the offered medi-
cines. Together with the systematic noncompliers, the
frequency of noncompliance within an eligible popula-
tion of 6779 individuals was only 0.71% (48/6779).
Amongst these few noncompliers, only 31 individuals re-
fused to ingest praziquantel and only nine individuals
noted reasons of bad side effects or bad taste/smell of
drugs. Although noncompliance was infrequent, the lack
of information dissemination by CMDs was apparent
(Fig. 2). Amongst the eligible individuals who were not
approached and offered any drugs by CMDs, 80.16%
(2982/3720) were unaware that any drugs were available
within the treatment period.
Any ordering effects of administering praziquantel first
on the subsequent compliance with or offer of albenda-
zole and ivermectin were investigated. Low rates of non-
compliance with albendazole and ivermectin were
observed for individuals who consumed praziquantel.
Amongst the eligible individuals who consumed prazi-
quantel and were offered albendazole, 0.49% (9/1823)
did not ingest albendazole. Amongst the eligible individ-
uals who consumed praziquantel and were offered iver-
mectin, 0.85% (14/1656) did not ingest ivermectin.
Concerning drug-specific treatment rates, the distribu-
tion of praziquantel had a positive spillover effect and
was strongly associated (p value < 0.0001) with the
Table 3 Treatment rates by drug and across community medicine distributors
Variable Obs. Mean (%) Std. Dev. (%) Min (%) Max (%)
% eligible individuals treated with at least one of PZQ, ALB, or IVM 59 26.08 21.79 0 84.25%
% eligible individuals treated with PZQ 59 23.88 20.24 0 72.24
% eligible individuals treated with ALB 59 20.44 19.89 0 82.78
% eligible individuals treated with IVM 59 16.95 18.49 0 82.45
PZQ praziquantel, ALB albendazole, IVM ivermectin
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increased distribution of albendazole and ivermectin
(Fig. 3).
Method of drug distribution
When all treated individuals were asked where they were
offered drugs, 85.44% (2600/3043) indicated at their
home, i.e. from the nationally approved door-to-door
method of drug distribution. There were 9.40% (286/
3043) of treated individuals who retrieved drugs directly
from a CMD’s home. Door-to-door drug distribution
also was predominantly used when both CMDs treated
the same individual; 81.79% (292/357) of these treated
individuals were offered drugs at their home. Only 6.16%
(22/357) of individuals treated by both CMDs had
retrieved drugs from the CMDs’ homes. All treated indi-
viduals who did not receive drugs at their home or at a
CMD’s home were offered treatment by CMDs at a cen-
tral point, e.g. a local health centre (0.56%, 17/3043), pri-
mary school (1.81%, 55/3043), the chairman’s home
(0.30%, 9/3043), or at a friend’s house (0.76%, 23/3043).
Only 1.74% (53/3043) of treated individuals did not
know the location of drug receipt.
Who was a CMD?
Characteristics of CMDs are presented in Table 4.
NTD-endemic communities selected CMDs, on average,
who were old compared to the median age in the study
villages (42.86 years; 88th percentile of age) and were
A B
Fig. 2 Reasons for refusal of treatment. PZQ praziquantel, ALB albendazole, IVM ivermectin. A treated individual was someone eligible for MDA
and who was offered and ingested at least one pill of PZQ, ALB, or IVM from a CMD during 1 month of MDA. a A breakdown of the specific
drugs and number of drugs that were offered, but not ingested amongst treated individuals is shown. Individuals did not provide reasons for
refusing specific drugs. Hence, if a treated individual did not ingest more than one offered drug, then the reason of refusal applied to all of the
drugs that were not ingested. Here, no more than one reason for refusing a drug was provided per individual, though no limit was imposed. b
The number of individuals, amongst individuals eligible for MDA, and their reasons for either refusing to ingest all offered drugs or for not being
offered any drugs are shown. Individuals who were offered drugs, but refused to ingest all of the drugs offered provided only one reason for
refusing treatment. The eligible individuals who were not offered any drugs provided up to two reasons for not being offered treatment. No
limits on the number of responses allowed were imposed
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moderately educated, i.e. completed only 1 year of edu-
cation after primary school. CMD turnover was low; in-
dividuals had been CMDs for an average of 8.71 years.
Approximately 50% of CMDs were female or belonged
to the majority tribe/religion of their village. Farming
was the most common occupation (74.58%). A small mi-
nority of fishermen/fishmongers (8.47%) also were
CMDs. The vast majority of CMDs engaged in good pre-
ventative health behaviours; 79.66% and 86.44% of
CMDs, respectively, retrieved drinking water from a pro-
tected source and owned a private home latrine. CMDs
were well established within their village; they belonged
to a household that had resided in the village for many
years (avg. 22.98) and 27.12% of CMDs held or had held
formal positions of power on the local council (village
government), as tribe/clan/religious leaders, or on the
beach management committees. Although national
MDA programmes instruct villages to nominate CMDs
through open community meetings, only 44.07% of
CMDs were selected in this manner. The remaining
CMDs were selected directly by a local council member
(50.85%) or by a village health team member (5.08%),
which is the lowest administrative medical unit in
Uganda.
Regarding the prosocial tendencies of CMDs, only
13.56% of CMDs were classified as altruistic. Nearly half
of CMDs (47.46%) displayed in-group biases, indicating
that CMDs are more likely to act altruistically towards
their close friends than towards strangers. Almost
one-third of CMDs had purposely sought at least one of
their current close friendships to establish links to some-
one in their village with high (formal) status. There was
little variation amongst CMDs with respect to the struc-
ture of their close friendships; most CMDs belonged to a
network of dense, closely knit friends (Additional file 1:
Table S3).
Profiles of best-performing CMDs
Only 28% (7/25) of the initial characteristics of CMDs
were relevant for predicting CMD treatment rates, i.e.
identified through the data-driven approach for variable
selection and included in the linear regression (Fig. 4,
Table 5, and Additional file 1: Table S4). The final sig-
nificant (p value < 0.05) determinants of treatment con-
cerned the friends, gender, occupation, and preventative
health behaviours of CMDs. How a CMD viewed their
friends and whether a CMD involved their friends with
MDA was related to how many people the CMD treated.
CMDs, who were more altruistic towards their friends
than towards strangers (positive in-group biases), were
predicted to treat 13.88% more individuals when com-
pared to CMDs without in-group biases. If a CMD had
friends who helped with MDA, then the CMD’s treat-




Fig. 3 Correlation between drug-specific treatment rates. Treatment rates achieved by CMDs (59 obs.) are shown. Treatment rates were measured
as the percentage of eligible individuals who were offered and had ingested the drug of interest. The drug-specific treatment rates, i.e. the
different outcomes for a CMD, were strongly, positively correlated. a Pearson’s r = 0.898, p value < 0.0001. b Pearson’s r = 0.858, p value< 0.0001. c
Pearson’s r = 0.959, p value < 0.0001
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the treatment rate of a CMD whose friends were not in-
volved with MDA.
Three personal characteristics of CMDs were associ-
ated with treatment. Female CMDs were predicted to
treat 11.96% fewer individuals than male CMDs. The
discrepancy in treatment rates between female and male
CMDs was not because CMDs only treated individuals
of the same gender. Amongst the eligible individuals
treated by female CMDs and male CMDs, 49.76% (611/
1228) were male and 50.00% (967/1934) were female, re-
spectively. Being a fisherman/fishmonger was associated
with a 14.93% increase in the percentage of individuals
treated when compared to the treatment rates of CMDs
from any other occupation. If a CMD belonged to a
household that retrieved drinking water from a pro-
tected source then the CMD was estimated to treat
Table 4 Characteristics of community medicine distributors
Variable All
CMDs
CMDs in ≤ 50th
percentileb




(n = 59) (n = 30) (n = 29) (n = 6)
Baseline altruism, no. (%) 8
(13.56)
3 (10.00) 5 (17.24) 0 (0)
In-group bias, no. (%) 28
(47.46)
11 (36.67) 17 (58.62) 1 (16.67)
Sought friends w/formal (high) status, no. (%) 18
(30.51)
12 (40.00) 6 (20.69) 2 (33.33)
CMD selected in community meeting, no. (%) 26
(44.07)
11 (36.67) 15 (51.72) 3 (50.00)
CMD selected by local council (vill. gov.), no. (%) 30
(50.85)
17 (56.67) 13 (44.83) 2 (33.33)
CMD selected by village health team, no. (%) 3 (5.08) 2 (6.67) 1 (3.45) 1 (16.67)
CMD’s friends help with MDA, no. (%) 44
(74.58)
20 (66.67) 24 (82.76) 5 (83.33)
Years as CMD, mean (Std. Dev.) 8.71
(4.53)
8.07 (4.62) 9.38 (4.43) 5.5 (4.76)
Age, mean (Std. Dev.) 42.86
(10.07)
40.20 (8.08) 45.62 (11.26) 41 (9.21)
Female, no. (%) 30
(50.85)
18 (60.00) 12 (41.38) 4 (66.67)
Education, mean (Std. Dev.) 8.29
(1.91)
8.07 (1.82) 8.52 (2.01) 8.17 (1.60)
Majority tribe, no. (%) 30
(50.85)
15 (50.00) 15 (51.72) 4 (66.67)
Majority religion, no. (%) 31
(52.54)
17 (56.67) 14 (48.28) 4 (66.67)
Farmer, no. (%)a 44
(74.58)
25 (83.33) 19 (65.52) 4 (66.67)
Fisherman/fishmonger, no. (%)a 5 (8.47) 1 (3.33) 4 (13.79) 0 (0)
Formal status: current/former local council (village gov.) member, tribe/clan/religious
leader, or beach management committee member, no. (%)
16
(27.12)
6 (20.00) 10 (34.48) 2 (33.33)
Household uses protected drinking water source, no. (%) 47
(79.66)
21 (70.00) 26 (89.66) 5 (83.33)
Household owns private home latrine, no. (%) 51
(86.44)
26 (86.67) 25 (86.21) 5 (83.33)
Home quality score, mean (Std. Dev.)c 9.66
(2.73)
9.60 (2.54) 9.72 (2.96) 9.5 (2.26)
Years since household settled in village, mean (Std. Dev.) 22.98
(11.29)
22.27 (10.88) 23.72 (11.85) 25.33 (10.88)
CMD community medicine distributor
aBase category is “other” occupations
b50th percentile of treatment rates achieved by CMDs = 17.95%. Treatment rates = % of eligible individuals within CMD’s village who the CMD treated with at least
one drug of praziquantel, albendazole, or ivermectin
cSum of all rankings (1–4) of materials for roof, floor, and wall (Additional file 1: supplementary methods)
A summary of CMD network indicators is provided in Additional file 1: Table S3
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13.43% more people when compared to a CMD whose
household used unsafe water sources. All analyses were
rerun at the household level where the outcome of inter-
est was at least one eligible person in the home who was
treated with at least one drug of praziquantel,
albendazole, and ivermectin; all results remained robust
(Additional file 1: Table S5 and Table S6). Concerning
the CMDs who did not treat anyone, only two character-
istics were shared. All six of the CMDs who treated no
one were not fishermen/fishmongers and were not clas-
sified as altruistic individuals. CMD characteristics were
associated with how many people CMDs chose to treat
as opposed to which drugs CMDs chose to administer
(Additional file 1: Table S7 and Table S8).
Fig. 4 Determinants of treatment rates of community medicine distributors. This figure shows the increase/decrease in the percentage of eligible
individuals treated with at least one drug of praziquantel, albendazole, or ivermectin by a CMD. The results are the coefficients of the linear
regression shown in Table 5. *p value < 0.05, **p value < 0.01, ± Network betweenness was not significant (p value > 0.05) when one outlier was
removed (Additional file 1: Table S4); 58/59 CMDs had network betweenness ≤ 3 whilst 1/59 CMDs had network betweenness = 11.58. In-group
bias is positive if the CMD was altruistic towards their friends and not altruistic towards strangers
Table 5 Determinants of treatment rates by community medicine distributors
Variablea Coef. Clustered robust SE p value 95% confidence interval
In-group biasb 0.139 0.059 0.025 0.019 0.259
Selected by local councilc − 0.085 0.053 0.121 − 0.194 0.024
Friends help with MDAd 0.084 0.040 0.041 0.004 0.165
Female − 0.120 0.057 0.043 − 0.235 − 0.004
Fisherman/fishmongere 0.149 0.040 0.001 0.067 0.232
Household uses protected drinking water source 0.134 0.040 0.002 0.053 0.216
Network betweennessf 0.030 0.008 0.001 0.013 0.047
Constant 0.095 0.050 0.067 − 0.007 0.197
Obs. 59, R2 = 0.331, F-stat. 13.69, F-stat. p value < 0.0001. Root mean squared error (RMSE) from 8-fold cross-validation = 0.183. Variables selected through Lasso
with 8-fold cross-validation. Mean squared error (MSE) of Lasso cross-validation = 0.076
aThe results shown are from an ordinary least squares regression with standard errors clustered by the village
bIn-group bias is positive if the CMD was altruistic towards their friends and not altruistic towards strangers
cThe base category includes CMD selection by community meeting or direct nomination from a village health team member
dMDA =mass drug administration
eThe base category for these occupations includes all other CMD occupations
fNetwork betweenness was not significant (p value > 0.05) when one outlier was removed (Additional file 1: Table S4) 58/59 CMDs had network betweenness ≤ 3
whilst 1/59 CMDs had network betweenness = 11.58
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Remarkably, no CMD met the WHO treatment target
for schistosomiasis, whereas only a single CMD (the
same CMD) met the WHO treatment targets for STHs
and lymphatic filariasis.
Role of CMD friends in MDA
For CMDs (44/59) whose friends were involved with
MDA, the exact role of those friend groups varied. Each
CMD provided at least one role for their friends; 67 re-
sponses in total were received from CMDs. The most
common to least common role of CMD friends was as
follows: spreading information about drug availability
(61.02%, 36/59 CMDs), convincing people to swallow
drugs (18.64%, 11/59 CMDs), informing CMDs about
village problems with MDA (16.95%, 10/59 CMDs), mo-
bilizing the community for MDA (6.78%, 4/59 CMDs),
finding people missed for treatment by CMDs (5.08%, 3/
59 CMDs), and monitoring CMDs and requiring them
to treat everyone in the village (5.08%, 3/59 CMDs).
To identify who exactly was a friend of a CMD, the
composition of CMD friend groups was investigated and
compared to the socioeconomic characteristics of the
CMD of interest (Fig. 5 and Additional file 1: supple-
mentary methods). On average, CMDs chose to befriend
individuals who were of the same gender, had similar
formal status in the village, shared preventative health
behaviours such as using protected water sources and
owning a private home latrine, and were alike with re-
gard to economic wealth as measured by home quality
scores. To a much lesser extent, friends also were similar
to CMDs concerning religion and occupation. CMDs on
average differed from their friends concerning aspects of
seniority; friends were dissimilar with respect to age,






Fig. 5 Similarity between community medicine distributors and their friends. Dashed lines show the mean value. All plots include all CMDs (59
obs.). Histogram bar widths = 0.25. a–k Show CMD homophily scores for all socioeconomic characteristics. Homophily is the measure of likeness
for a group of individuals; homophily scores for CMDs reveal to what extent the friend group of a CMD is similar to the CMD of interest when
compared by socioeconomic characteristics (Additional file 1: supplementary methods). A score of − 1 indicates perfect similarity, i.e. friends have
the same characteristic/value as the CMD for the variable of interest, whilst + 1 indicates perfect dissimilarity, i.e. no friends have the same
characteristic/value as the CMD for the variable of interest
Chami et al. BMC Medicine           (2019) 17:69 Page 11 of 16
settlement in the village. Notably, the composition of
friend groups did not affect (p value > 0.05) CMD treat-
ment rates (Additional file 1: Table S9 and Table S10).
Discussion
Despite a number of countries with low/stagnant MDA
treatment rates [3], WHO resolutions (WHA65.21,
WHA50.29, WHA54.19) call for elimination of schisto-
somiasis, lymphatic filariasis, and STHs as public health
problems [25–27]. Current WHO targets for morbidity
control are at least 75% treatment of at-risk school-aged
children for schistosomiasis and STHs, and for elimin-
ation as a public health problem are at least 65% treat-
ment of at-risk school-aged children and adults for
lymphatic filariasis. In our study area, treatment rates
were well below estimated WHO targets for either con-
trolling morbidity or curbing transmission. For 6779 eli-
gible individuals across 31 villages, the percentage of
eligible individuals treated with at least one drug of
praziquantel, albendazole, or ivermectin was 44.89%—a
notable decrease from 56.77% observed only 3 years
prior for MDA in our study villages [17]. Substantial
variation in treatment rates amongst CMDs was ob-
served (0–84.25%) and analyzed to profile the
best-performing CMDs.
Treatment rates were entirely reliant on CMD charac-
teristics rather than the willingness of the recipient to
ingest medicines. CMDs were unpaid volunteers apart
from remuneration for training. There is a
well-established assumption that volunteers are altruistic
[28]. We showed it was incorrect to assume CMDs were
altruistic because they were volunteers. Only 13.56% of
CMDs were classified as altruistic. These results accord
with a previous tracking of MDA, which revealed CMDs
are less likely to treat marginalized individuals who are
most in need of treatment [15, 19]. Furthermore, we
identified inactive CMDs within MDA programmes. The
CMDs who did not treat anyone shared a common char-
acteristic—none were classified as altruistic, i.e. having
prosocial tendencies. MDA programmes may want to in-
vestigate the replacement of inactive CMDs. The CMDs
who treated no one or who were in the bottom 50th per-
centile of treatment rates were serving as CMDs, re-
spectively, for an average of over 5 and 8 years. If these
CMDs were inactive during the whole time period that
they were serving as CMDs, then these individuals might
have undermined disease control. In our study villages,
the high prevalence of S. mansoni and hookworm has
persisted despite over a decade of MDA. There are two
strands of research required to identify the conditions of
CMD replacement or proactive elimination. First, it
remains an open question as to what treatment rate
cutoffs should be considered as an indicator of poor
performance for individual CMDs or conversely as the
treatment targets to be achieved by individual CMDs for
disease control. The conservative cutoff of a treatment
rate of zero might be too low for MDA programmes to
achieve WHO targets. Second, future work should inves-
tigate the use of prospective surveys to assess CMD
altruism in order to potentially actively eliminate the
CMDs without an intrinsic inclination/motivation to
help other individuals.
Here, we focused on the observed performance of
CMDs in order to provide, to our knowledge, the first
measure of treatment rates for individual CMDs and the
determinants of those treatment rates. In contrast, other
works in our study area have highlighted the challenges
faced by CMDs from their perspectives [11, 29],
although the correlation with treatment rates was not
examined. Addressing the perspective of CMDs was be-
yond the scope of this study, in particular to avoid inter-
fering with the tracking of routine MDA. However, our
findings present new avenues for future research. There
might be a need to assess whether or not the character-
istics of best/poor-performing CMDs are representative
of nuanced challenges that vary between CMDs. In this
light, our methodology for measuring treatment rates for
individual CMDs may be applied to MDA in other geo-
graphic contexts. Afterwards, qualitative surveys may be
used to examine how challenges vary from the perspec-
tive of CMDs and whether or not such challenges are as-
sociated with the profiles of the best-performing CMDs.
Previous research in our study area suggests that such
profiles may be indicative of the (lack of ) social biases of
CMDs towards MDA recipients [15]. Apart from the
perspective of CMDs, there are challenges that face all
CMDs in our study area: (1) no payment despite remu-
neration for training and hence opportunity costs for be-
ing a CMD, (2) the same level of perhaps limited
monitoring by district officials, (3) a limited timeframe
for MDA that is recommended by the national pro-
grammes, and (4) additional possibly conflicting health
responsibilities as all CMDs are part of the village health
team [11, 17, 29]. Importantly, one directly observed
challenge for six CMDs was having a partner CMD who
treated no one. Despite this impressive challenge, two
out of six of the CMDs were able to still treat at least
60% of eligible individuals within their villages, which is
in the 90th percentile of CMD treatment rates. To over-
come challenges common to all CMDs, our results
showed that the best-performing CMDs involve their
close friends to help with MDA-related tasks.
For schistosomiasis, two aspects of MDA implementa-
tion are considered formidable problems: treatment of
high-risk groups and the distribution of praziquantel.
Fishermen/fishmongers, who have high schistosome ex-
posure through frequent freshwater contact, have been
suggested as ignored in MDA [30]. Here, we showed
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that fishermen/fishmongers not only were active CMDs,
but also were likely to treat the most people. These find-
ings suggest that selecting CMDs within groups at
high-risk of endemic NTDs may increase treatment
rates. Amongst all medicines distributed with MDA,
praziquantel often is purported as the “showcase” drug
for adverse events or poor taste and, in turn, is assumed
to result in low rates of administration by CMDs or in-
gestion by MDA recipients [29]. These common conjec-
tures were not upheld when praziquantel treatment
rates were tracked during 1 month of MDA. Praziquan-
tel was most often administered (40.99%) by CMDs
when compared to albendazole (36.29%) or ivermectin
(29.74%). Only 1.28% (31/2424) of eligible individuals
had refused to ingest praziquantel when offered. More-
over, a maximum of 0.37% (9/2424) of eligible individ-
uals had refused to ingest praziquantel due to bad side
effects or bad smell/taste. These findings indicate that
the causes of low praziquantel treatment rates should
not be considered as unique when compared to other
drugs administered with MDA. In the context of inte-
grated MDA where multiple NTDs are treated, as was
the case in our study, we found no support to indicate
that praziquantel should not be administered before
other drugs. Consuming praziquantel first did not have a
negative impact on subsequent participant compliance
with albendazole or ivermectin. Concerning treatment
rates, the distribution of praziquantel was positively as-
sociated with albendazole and ivermectin treatment
rates. Hence, there was no evidence that CMDs experi-
enced any difficulties with praziquantel administration
that affected the subsequent distribution of albendazole
or ivermectin.
Gender parity is central to MDA programmes [31];
national programmes instruct villages to select one male
and one female CMD. Across our study villages, gender
balance was observed amongst CMDs (50.85% female).
There is a need to scrutinize why gender balance is a
requirement of community-based MDA. Being female
was associated with 11.96% fewer individuals treated. An
inability/unwillingness to treat the opposite sex could
not explain the lower treatment rates achieved by female
CMDs; 49.76% of the people treated by female CMDs
were male. Future research might investigate cultural
barriers, such as child-rearing duties, which prevent
female CMDs from treating more individuals. This ana-
lysis will not be straightforward. Female CMDs may have
less time for MDA perhaps due to their domestic duties.
However, in our study, this aspect might already have
manifested in who ultimately became a CMD, assuming
that older women have fewer child-caring responsibil-
ities. The average age of female CMDs was 40.40 years
(std. dev. 9.38), which was old relative to other females
in the study area (87th percentile of age). Even with the
assumption that child-rearing or other responsibilities
hinder the performance of female CMDs, social norms
exist within our study area where the women are re-
sponsible for the medical care of their family members
[32]. Such norms might be extended to the village and
act as a counter pressure against familial duties, thereby
encouraging female CMDs to be high performers in
order to meet community expectations. An open ques-
tion remains concerning whether the balance of CMD
characteristics affects MDA and whether having a criter-
ion for CMDs based on gender is justifiable for purposes
not related to increasing treatment rates such as empow-
ering women.
In accord with previous MDA tracking in our study
area [15, 17, 19], we questioned the proposed capacity
constraints of CMDs [9, 11]. It has been suggested that
more than two CMDs per village are needed for MDA
[9, 11]. Yet, we found that 10.17% (6/59) of CMDs did
not treat a single person during 1 month of MDA. There
is a possibility that CMDs who treated few or no individ-
uals were engaged with other tasks required for MDA
such as sensitizing/mobilizing the community, register-
ing households, or disseminating information about drug
availability. However, over 80% of the untreated eligible
individuals did not know that drugs were available dur-
ing our study period. This result suggests that it is highly
unlikely that we have omitted MDA-related tasks that
would increase/change the CMD’s contribution (and
workload) beyond that measured here with treatment
rates. Previous work in our study area corroborates this
assumption; CMDs were found to register and mobilize
individuals and households not before treatment as
trained by the national programme, but at the time of
treatment [17]. Furthermore, no support was found to
explain the uneven CMD contributions as attributable to
a negotiation between CMDs about how to split MDA
work; we controlled for village-level variation that would
explain individual-level CMD variation. Future research
is needed to address what combination of CMDs’ attri-
butes results in one CMD not performing MDA duties.
Additional studies should examine whether imbalances
in social status between CMDs affect which CMD
administers treatment. Little is known about how CMD
interactions and the balance of CMD personal character-
istics affect village-level treatment rates.
Friends of CMDs influenced MDA treatment rates
[17]. CMDs who involved their friends with drug distri-
bution were estimated to treat 8.43% more people when
compared to CMDs whose friends did not help with
MDA. The value placed on CMD friends’ opinions also
affected treatment rates. In-group bias was associated
with a 13.88% increase in treatment rates when com-
pared to CMDs without in-group biases. The exact
structure of CMDs’ friendships did not affect treatment
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rates. This result differs from findings at the village level
[17] due to the limitation of the network approximation
used here; only CMD-nominated friendships (outgoing
connections) were examined as opposed to full village
networks. These partial networks were denser and less
varied than actual CMD networks extracted from
complete village networks [17]. The influence of the
friends of CMDs on treatment outcomes may suggest a
need to amend what constitutes a “village affair” for
MDA. The selection of CMDs through community-wide
meetings is seen as a key driver of empowering local
ownership of MDA and ideally increasing treatment
rates. Only 44.07% of CMDs were selected through
community-wide meetings, whereas 50.85% were se-
lected directly by the local council (village government).
The selection of CMDs through community-wide
meetings versus other methods of local selection had no
association with treatment rates. This result suggests
that community-wide meetings are not necessarily a key
component of turning MDA into a village affair. In our
study, the friends of high-performing CMDs assisted
with turning MDA into a village affair. These friends
played a key role in informing individuals about available
treatment. A better informed target population has
greater capacity and better communication channels to
provide feedback to CMDs [17]. Importantly, CMDs
with friends who were involved with MDA were esti-
mated to treat more individuals. MDA programmes
should consider encouraging nominations of CMDs with
supportive friendship groups and formally including
friends of CMDs during MDA training. Informing the
friends of CMDs of ongoing MDA and requesting that
the friends help disseminate information and mobilize
the community would be an easily testable and inexpen-
sive intervention.
We presented, to our knowledge, the first methodology
and initial empirical results to evaluate individual CMDs.
Future work may build on our analysis by aiming to track
CMD performance over several years. Annual
cross-sectional monitoring of CMDs might be conducted
through sentinel site surveys in select representative com-
munities. These surveys may enable the observation of
any time-varying aspects of CMD performance over con-
secutive rounds of MDA. There also remains a need to
evaluate drug distributor performance in other MDA set-
tings. The 31 villages studied here do not capture the
breadth of contexts where MDA for NTDs is ongoing in
Sub-Saharan Africa. We studied (1) a rural context with
high transmission of an endemic NTD that has received
repeated annual MDA, (2) a mature community-based
and integrated MDA programme, and (3) door-to-door
drug distribution by village-selected CMDs. There re-
mains a need to measure the performance of CMDs, other
volunteers, or employed government health workers who
conduct MDA in other geographic, programmatic, and
NTD settings. Potential aspects of MDA that remain to be
studied for drug distributor performance include urban
environments, low transmission areas, immature/new
MDA programmes, non-integrated MDA, and areas using
predominantly central point (drug collection/pick-up)
distribution methods. If our findings are reproduced
overtime in various settings, then a profile with the shared
characteristics of high-performing CMDs might be estab-
lished for a typical MDA programme for NTDs.
Conclusions
Evidence-based guidelines for CMD selection and moni-
toring are needed. Here, we questioned key assumptions
of community-based MDA and showed that CMD char-
acteristics and CMDs’ involvement of friend groups may
be used to better select and monitor CMD performance.
Our findings also revealed two methodological ap-
proaches that may simplify MDA evaluation. The per-
centage of households and individuals treated was nearly
perfectly positively correlated, and all results were robust
at both household and individual levels. This methodo-
logical finding suggests that household-level outcomes
measuring treatment of at least one eligible person in
the home may be used to approximate individual-level
treatment. Treatment rates by individual CMDs should
now be evaluated. In our study, all respondents knew
which CMD offered drugs to whom, suggesting that the
collection of information concerning who treated who
may be easily incorporated into routine MDA monitor-
ing. To increase treatment rates with community-based
MDA, friends of CMDs should be involved with drug
distribution and national programmes should help guide
endemic communities to evaluate current CMDs and to
replace poor-performing CMDs.
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